# TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Source: https://onco.cc/trials/nct05948813/  
OnCo record `nct05948813` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TY-9591 and Osimertinib in non-small-cell lung cancer and brain and spinal cord tumours, run by TYK Medicines, Inc, now recruiting.

## Summary

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases is a phase 2 interventional study registered as NCT05948813 by TYK Medicines, Inc, with 420 participants planned, started 2023-08-17 and due to reach its primary completion in 2025-12-15. Interventions recorded: TY-9591 and Osimertinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05948813
- Phase: 2
- Setting: A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain Metastases
- Sponsor: TYK Medicines, Inc
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT05948813: https://clinicaltrials.gov/study/NCT05948813

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [TY-9591](https://onco.cc/drugs/ty-9591/)

---
JSON: https://onco.cc/api/v1/entities/nct05948813.json